Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U—13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: The present invention provides a diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive capacity which imposes less burden to subjects and which is capable of obtaining objective test results in a short period of time. A diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive capacity, comprising succinic acid labeled with a stable isotope 13C or a pharmaceutically acceptable salt thereof.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent is provided. Further, a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents is provided.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R113 Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A diagnostic agent for pancreatic exocrine function comprising an amino acid or a peptide containing at least one 13C or 14C atom, or a pharmaceutically acceptable salt thereof other than Bz-Tyr-13C-PABA is provided. A 13C- or 14C-labeled compound represented by the following formula (II): X2—R2—Y2—Z1 ??(II) or a salt thereof, wherein X2 is a hydrogen atom or a protecting group, R2 is a peptide of 2 to 5 amino acids, an amino acid or a single bond, Y2 is an amino acid, Z1 is an amino acid optionally having a protecting group, and at least one of the amino acids in R2, Y2 and Z1, or at least one of the protecting groups in X2 and Z1 when the protecting groups contain a carbon atom, is 13C or 14C-labeled.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A isotopic gas of high purity is obtained at low cost, wherein for example, in a case of separating 13CH4 from methane gas and obtaining 13CH4 of high purity, the enrichment of 13CH4, using the difference in adsorption of 12CH4 and 13CH4 onto an adsorbing material, is performed up to a certain concentration, and thereafter, 13CH4 is enriched by a separation method by distillation that uses the difference in boiling point.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y‘??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent; and a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents for one or ones having high medicative efficacy and/or a small side effect are provided.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C -amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.